Christi Shaw to Depart Gilead and Kite Leadership
On Friday, February 17, Gilead / Kite announced (press release) that Christi Shaw (Kite’s CEO) decided to depart by the end of Q1 2023. Below, Celltelligence provides insights on Shaw’s tenure in Kite, while discussing the profile of her potential replacement.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.